Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Charity D. Scripture"'
Autor:
Yutaka Fujiwara, Kazuhiko Nakagawa, Ikuko Yasuda, Hiroaki Akamatsu, Keisuke Kirita, Masayuki Shintani, Shintaro Kanda, Matthew P. Kosloski, Kentaro Tanaka, Shunsuke Teraoka, Hibiki Udagawa, Isamu Okamoto, Sumiko Okubo, Charity D. Scripture, Masayuki Takeda, Tomohide Tamura
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 135
Objectives Rovalpituzumab tesirine (Rova-T™) is an antibody-drug conjugate that targets delta-like protein 3 (DLL3) on small cell lung cancer (SCLC) tumors, is internalized and releases the toxin pyrrolobenzodiazepine to induce cell death. This ope
Autor:
Masayuki Takeda, Masayuki Shintani, Hibiki Udagawa, Isamu Okamoto, Ikuko Yasuda, Tomohide Tamura, Hiroaki Akamatsu, Charity D. Scripture, Shunsuke Teraoka, Rachel S Leibman, Kentaro Tanaka, Keisuke Kirita, Sumiko Okubo, Kazuhiko Nakagawa, Shintaro Kanda, Yutaka Fujiwara
Publikováno v:
Journal of Clinical Oncology. 37:8557-8557
8557 Background: SCLC rapidly recurs after first-line platinum therapy, and while several agents are approved in the relapsed/refractory setting, there is no approved agent or existing standard of care for third-line in Japan. Rovalpituzumab tesirine
Autor:
Charity D. Scripture, Giuseppe Curigliano, Shekman Wong, Ticiana Leal, Laurent Greillier, Neal Ready, Jyoti D. Patel, Emin Avsar, Jyoti Malhotra, Daniel Morgensztern, Gilles Robinet, Ricardo Valenzuela, Giovanni Selvaggi, Petros Nikolinakos, Satwant Lally, Jonathan M. Lehman, John Wrangle, Eric Dansin, Benjamin Besse, Melissa Lynne Johnson
Publikováno v:
Journal of Clinical Oncology. 37:8516-8516
8516 Background: Rovalpituzumab tesirine (Rova-T™) is an antibody-drug conjugate targeting DLL3, a Notch ligand expressed in SCLC but not normal tissue. Nivo ± Ipi has activity in 2L+ SCLC. Preliminary data suggest Rova-T may result in immunogenic
Autor:
Hiroaki Akamatsu, Shekman Wong, Kentaro Tanaka, Isamu Okamoto, Sumiko Okubo, Ikuko Yasuda, Charity D. Scripture, Shintaro Kanda, Hibiki Udagawa, Tomohide Tamura, Masayuki Takeda
Publikováno v:
Annals of Oncology. 29:vii57
Autor:
Alex Sparreboom, William D. Figg, Charity D. Scripture, Jacquin Jones, Neil Desai, Erin R. Gardner, Jeanny B. Aragon-Ching, William L. Dahut, Michael J. Hawkins
Publikováno v:
Clinical Cancer Research. 14:4200-4205
Purpose: Abraxane (ABI-007) is a 130-nm albumin-bound (nab) particle formulation of paclitaxel, devoid of any additional excipients. We hypothesized that this change in formulation alters the systemic disposition of paclitaxel compared with conventio
Publikováno v:
Current Drug Metabolism. 7:677-685
Despite its controversial past, thalidomide is currently under investigation for the treatment of several disease types, ranging from inflammatory conditions to cancer. The mechanism of action of thalidomide is complex and not yet fully understood, b
Publikováno v:
Expert Opinion on Drug Metabolism & Toxicology. 2:17-25
Interindividual differences in efficacy and toxicity of cancer chemotherapy are especially important given the narrow therapeutic index of these drugs. Pharmacokinetic and pharmacodynamic responses to chemotherapy are difficult to predict in a partic
Autor:
Kyunghwa Hwang, William D. Figg, Alex Sparreboom, Martin Gutierrez, Shivaani Kummar, Charity D. Scripture
Publikováno v:
Journal of Chromatography B. 830:35-40
A rapid method was developed for the quantitative determination of the novel heat shock protein 90 inhibitor, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG; NSC707545), in human plasma. Calibration curves were constructed, and were ana
Publikováno v:
Expert Review of Anticancer Therapy. 5:605-611
Androgen deprivation therapy is a mainstay for the treatment of advanced prostate cancer. Hormonal therapy commonly consists of injection of gonadotropin hormone-releasing hormone agonists. Based on the need for improved convenience of administration
Autor:
Christy S. Scott, Mary Jayne Kennedy, Andrea Gaedigk, Charity D. Scripture, Angela D. M. Kashuba, Gregory L. Kearns
Publikováno v:
Clinical Pharmacology & Therapeutics. 75:163-171
The activities of hepatic cytochrome P450 (CYP) 1A2, N-acetyltransferase 2 (NAT-2), xanthine oxidase (XO), and CYP2D6 were evaluated in 12 young children (aged 3-8 years) with mild cystic fibrosis (CF) and 12 age-matched healthy control subjects by u